Sofosbuvir plus daclatasvir as an alternative for patients on haemodialysis with genotype 2 hepatitis C virus infection

Enferm Infecc Microbiol Clin (Engl Ed). 2018 Aug-Sep;36(7):457. doi: 10.1016/j.eimc.2017.10.012. Epub 2017 Dec 6.

[Article in English, Spanish]

Authors

Jara Llenas-García¹, Sergio Padilla², Mar Masiá², Félix Gutiérrez²

Affiliations

¹ Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de l'Almazara, Elche, Alicante, Spain; Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Valencia, Spain. Electronic address: [email protected].
² Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de l'Almazara, Elche, Alicante, Spain; Universidad Miguel Hernández, Alicante, Spain.

PMID: 29217095
DOI: 10.1016/j.eimc.2017.10.012

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antiviral Agents / administration & dosage
Antiviral Agents / therapeutic use*
Carbamates
Drug Interactions
Drug Monitoring
Drug Therapy, Combination
Genotype
Hepacivirus / genetics
Hepacivirus / isolation & purification
Hepatitis C / complications
Hepatitis C / drug therapy*
Humans
Imidazoles / administration & dosage
Imidazoles / therapeutic use*
Male
Middle Aged
Polypharmacy
Pyrrolidines
Renal Dialysis*
Renal Insufficiency, Chronic / complications*
Renal Insufficiency, Chronic / therapy
Sofosbuvir / administration & dosage
Sofosbuvir / therapeutic use*
Valine / analogs & derivatives

Substances

Antiviral Agents
Carbamates
Imidazoles
Pyrrolidines
Valine
daclatasvir
Sofosbuvir